Modeling asthma: Pitfalls, promises, and the road ahead

Journal of Leukocyte Biology

Volumn 104, Issue 1, 2018, Pages 41-48

  Rosenberg, Helene F ^a   Druey, Kirk M ^a  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

airways; eosinophils; inflammation; leukocytes; veterinary

Indexed keywords

ALLERGEN; ANTIINFLAMMATORY AGENT; BIOLOGICAL PRODUCT; BRONCHODILATING AGENT; CORTICOSTEROID; CYTOKINE; DUPILUMAB; EPINEPHRINE; ISOPRENALINE; LEUKOTRIENE RECEPTOR BLOCKING AGENT; METHACHOLINE; OMALIZUMAB; PHOSPHODIESTERASE IV INHIBITOR; PLACEBO; PROTEIN TYROSINE KINASE INHIBITOR; STEROID; THEOPHYLLINE;

ADAPTIVE IMMUNITY; AIRWAY; AIRWAY DYNAMICS; ALLERGIC AIRWAY INFLAMMATION; ALLERGIC ASTHMA; ASTHMA; BIOLOGICAL THERAPY; CLINICAL FEATURE; CORTICOSTEROID THERAPY; DISEASE EXACERBATION; DOMESTIC CAT; DRUG EFFICACY; DYSPNEA; GUINEA PIG; HORSE; HUMAN; IMMUNOTHERAPY; INFLAMMATION; LUNG FUNCTION; MEDICAL HISTORY; NONHUMAN; OBSTRUCTIVE AIRWAY DISEASE; PATHOGENESIS; PRIORITY JOURNAL; RESPIRATORY TRACT ALLERGY; RESPIRATORY TRACT DISEASE; REVIEW; RODENT; TH2 CELL; ANIMAL; DISEASE MODEL;

ANIMALS; ASTHMA; DISEASE MODELS, ANIMAL; HUMANS;

EID: 85042089541     PISSN: 07415400     EISSN: 19383673     Source Type: Journal    
DOI: 10.1002/JLB.3MR1117-436R     Document Type: Review

References (99)

1. BethesdaMDExpert Panel Report-3 from the National Heart, Lung and Blood Association, https://www.nhlbi.nih.gov/files/docs/guidelines/asthsumm.pdf
2. Jartti T, Gern JE. Role of viral infections in the development and exacerbation of asthma in children. J Allergy Clin Immunol. 2017;140:895–906.
3. Castillo JR, Peters SP, Busse WW. Asthma exacerbations: pathogenesis, prevention and treatment. J Allergy Clin Immunol Pract. 2017;5:918–927.
4. Schiavoni G, D'Amato G, Afferni C. The dangerous liaison between pollens and pollution in respiratory allergy. Ann Allergy Asthma Immunol. 2017;118:269–275.
5. Zhang Z, Reponen T, Hershey GK. Fungal exposure and asthma: igE and non-IgE-mediated mechanisms. Curr Allergy Asthma Rep. 2016;16:86.
6. Brightling CE. Chronic obstructive pulmonary disease phenotypes, biomarkers and prognostic indicators. Allergy Asthma Proc. 2016;37:432–438.
7. Kumar RK, Herbert C, Foster PS. Mouse models of acute exacerbations of allergic asthma. Respirology. 2016;21:842–849.
8. Lloyd CM. Building better mouse models of asthma. Curr Allergy Asthma Rep. 2007;7:231–236.
9. Shin YS, Takeda K, Gelfand EW. Understanding asthma using animal models. Allergy Asthma Immunol Res. 2009;1:10–18.
10. Jacobsen EA, Lee NA, Lee JJ. Re-defining the unique roles for eosinophils in allergic respiratory inflammation. Clin Exp Allergy. 2014;44:1119–1136.
11. Epstein MM, Tilp C, Erb KJ. The use of mouse asthma models to successfully discover and develop novel drugs. Int Arch Allergy Immunol. 2017;173:61–70.
12. Chapman DG, Tully JE, Nolin JD, Janssen-Heininger YM, Irvin CG. Animal models of allergic airways disease: where we are and where to next. J Cell Biochem. 2014;115:2055–2064.
13. Persson CGA. Mice are not a good model of human airway disease. Am J Respir Crit Care Med. 2002;166:6–7.
14. Williams K, Roman J. Studying human respiratory disease in animals–role of induced and naturally occurring models. J Pathol. 2016;238:220–232.
15. Gershwin LJ. Comparative immunology of allergic responses. Ann Rev Anim Biosci. 2015;3:327–346.
16. Sakula A. Henry Hyde Salter (1823–71): a biographical sketch. Thorax. 1985;40:887–888.
17. Spina D, Page CP. Xanthines and phosphodiesterase inhibitors. Handb Exp Pharmacol. 2017;237:63–91.
18. Holgate ST. A brief history of asthma and its mechanisms to modern concepts of disease pathogenesis. Allergy Asthma Immunol Res. 2010;2:165–171.
19. Harris MS. Cortisone in treatment of bronchial asthma. Calif Med. 1951;75:85–88.
20. Vernon DR, Macleod JM, Kerr JW. A 12-month double-blind assessment of betamethasone valerate aerosol in the management of asthma. Clin Allergy. 1976;6:261–266.
21. Ishizaka K, Ishizaka T. Identification of IgE. J Allergy Clin Immunol. 2016;137:1646–1650.
22. Saito H, Ishizaka T, Ishizaka K. Mast cells and IgE: from history to today. Allergol Int. 2013;62:3–12.
23. Mosmann TR, Coffman RL. TH1 and TH2 cells: different patterns of lymphokine secretion lead to different functional properties. Ann Rev Immunol. 1989;7:145–173.
24. Ebbo M, Crinier A, Vely F, Vivier E. Innate lymphoid cells: major players in inflammatory diseases. Nat Rev Immunol. 2017;17:665–678.
25. Fajt ML, Wenzel SE. Development of new therapies for severe asthma. Allergy Asthma Immunol Res. 2017;9:3–14.
26. Ray A, Raundhal M, Oriss TB, Ray P, Wenzel SE. Current concepts of severe asthma. J Clin Invest. 2016;126:2394–2403.
27. Chung KF. Precision medicine in asthma: linking phenotypes to targeted treatments. Curr Opin Pulm Med. 2018;24:4–10.
28. Russell RJ, Brightling C. Pathogenesis of asthma: implications for precision medicine. Clin Sci. 2017;131:1723–1735.
29. Svenningsen S, Nair P. Asthma endotypes and an overview of targeted therapy for asthma. Front Med. 2017;4:158.
30. Brusselle GG, Vanderstichele C, Jordens P, et al. Azithromycin for prevention of exacerbations in severe asthma (AZISAST): a multicentre randomized double-blind placebo-controlled trial. Thorax. 2013;68:322–329.
31. Chupp G, Laviolette M, Cohn L, et al. Long-term outcomes of bronchial thermoplasty in subjects with severe asthma: a comparison of 3-year follow-up results from two prospective multi-center studies. Eur Respir J. 2107;31:50.
32. Castro M, Rubin A, Laviolette M, Hanania NA, Armstrong B, Cox G, AIR2 Trial Study Group. Persistence of effectiveness of bronchial thermoplasty in patients with severe asthma. Ann Allergy Asthma Immunol. 2011;107:65–70.
33. Humbert M, Busse W, Hanania NA. Controversies and opportunities in severe asthma. Curr Opin Pulm Med. 2018;24:83–93.
34. Poulakos MN, Cargill SM, Waineo MF. Mepolizumab for the treatment of severe eosinophilic asthma. Am J Health Syst Pharm. 2017;74:963–969.
35. Chupp GL, Bradford ES, Albers FC, et al. Efficacy of mepolizumab add-on therapy on health-related quality of life and markers of asthma control in severe eosinophilic asthma (MUSCA): a randomised, double-blind, placebo-controlled parallel-group, multicentre, phase 3b trial. Lancet Respir Med. 2017;5:390–400.
36. Wenzel S, Ford L, Pearlman D, et al. Dupilumab in persistent asthma with elevated eosinophil levels. N Engl J Med. 2013;368:2455–2466.
37. Wenzel S, Castro M, Corren J, et al. Dupilumab efficacy and safety in adults with uncontrolled persistent asthma despite use of medium-to-high-dose inhaled corticosteroids plus a long-acting β2 agonist: a randomised double-blind placebo-controlled pivotal phase 2b dose-ranging trial. Lancet. 2016;388:31–44.
38. Corren J, Parnes JR, Wang L, et al. Tezepelumab in adults with uncontrolled asthma. N Engl J Med. 2017;377:936–946.
39. Hau J. Chapter 1. Animal models for human diseases. An overview. In: Conn PM, ed. Sourcebook of Models for Biomedical Research. Totowa NJ: Humana Press; 2008:3–8.
40. Kumar RK, Herbert C, Foster PS. The “classical” ovalbumin challenge model of asthma in mice. Curr. Drug Targets. 2008;9:485–494.
41. Gao P. Sensitization to cockroach allergen: immune regulation and genetic determinants. Clin Dev Immunol. 2012;2012:563760.
42. Ochkur SI, Jacobsen EA, Protheroe CA, et al. Co-expression of IL-5 and eotaxin-2 in mice creates an eosinophil-dependent model of respiratory inflammation with characteristics of severe asthma. J Immunol. 2007;178:7879–7889.
43. Gour N, Wills-Karp M. IL-4 and IL-13 signaling in allergic airway disease. Cytokine. 2015;75:68–78.
44. Foster PS, Maltby S, Rosenberg HF, et al. Modeling TH2 responses and airway inflammation to understand fundamental mechanisms regulating the pathogenesis of asthma. Immunological Rev. 2017;278:20–40.
45. Trzil JE, Reinero CR. Update on feline asthma. Vet Clin Small Anim. 2014;44:91–105.
46. Bullone M, Lavoie JP. Asthma “of horses and men” –how can equine heaves help us better understand human asthma immunopathology and its functional consequences. Mol Immunol. 2015;66:97–105.
47. Jensen-Jarolim E, Einhorn L, Herrmann I, Thalhammer J, Panakova L. Pollen allergies in humans and their dogs, cats and horses: differences and similarities. Clin Transl Allergy. 2015;5:15.
48. Darowski MJ, Hannon VM, Hirshman CA. Corticosteroids decrease airway hyperresponsiveness in the Basenji-Greyhound dog model of asthma. J Appl Physiol. 1985;66:1120–1126.
49. Hug LA, Baker BJ, Anantharaman K, et al. A new view of the tree of life. Nat Microbiol. 2016;1:16048.
50. Graur D, Li W-H. Fundamentals of Molecular Evolution. Sunderland, MA: Sinauer Associates; 1991:139.
51. Mouse genome sequencing consortium et al., 2002. Initial sequencing and comparative analysis of the mouse genome. Nature 420: 520–562.
52. Kapetanovic R, Arrifin JK, Sweet MJ. Evolutionary divergence in human versus mouse innate immune genes. In: Pontarotti Pierre, ed. Evolutionary Biology: Genome Evolution, Speciation, Coevolution and Origin of Life. Heidelberg, Germany: Springer; 2014:115–155.
53. Silver LM. Mouse Genetics: Concepts and Applications. Oxford: Oxford University Press; 2008. http://www.informatics.jax.org/silver/. also available at.
54. Bagg HJ. Individual differences and family resemblances in animal behavior. Amer Nat. 1916;50:222–236.
55. Potter M. History of the BALB/c family. In: Potter M, ed. Current Topics in Microbiology and Immunology. Berlin: Springer-Verlag; 1985:1–5. The BALB/c mouse.
56. Jackson RB, Little CC. The existence of non-chromosomal influence in the incidence of mammary tumors in mice. Science. 1933;78:465–466.
57. Simon MM, Greenaway S, White JK, et al. A comparative phenotypic and genomic analysis of C57BL/6J and C57BL/6N mouse strains. Genome Biology. 2013;14:R82.
58. Boot R, Walvoort HC. Otitis media in guinea pigs: pathology and bacteriology. Lab Anim. 1986;20:242–248.
59. Keyhani M, Naghshineh R. Spontaneous epizootic of pneumococcus infection in guinea-pigs. Lab Anim. 1974;8:47–49.
60. Wright JL, Postma DS, Kerstjens HA, Timens W, Whittaker P, Churg A. Airway remodeling in the smoke-exposed guinea pig model. Inhal Toxicol. 2007;19:915–923.
61. Canning BJ, Chou Y. Using guinea pigs in studies relevant to asthma and COPD. Pulm Pharmacol Ther. 2008;21:702–720.
62. Gleich GJ. The eosinophil: new aspects of structure and function. J Allergy Clin Immunol. 1977;60:73–82.
63. Takatsu K. Interleukin-5 and IL5 receptor in health and diseases. Proc Jpn Acad Ser B Phys Biol Sci. 2011;87:463–485.
64. Takatsu K, Nakajima H. IL-5 and eosinophilia. Curr Opin Immunol. 2008;20:288–294.
65. Parulekar AD, Kao CC, Diamant Z, Hanania NA. Targeting the interleukin-4 and interleukin-13 pathways in severe asthma: current knowledge and future needs. Curr Opin Pulm Med. 2018;24:50–55.
66. Bagnasco D, Ferrando M, Varricchi G, Passalacqua G, Canonica GW. A critical evaluation of anti-IL-13 and anti-IL4 strategies in severe asthma. Int Arch Allergy Immunol. 2016;170:122–131.
67. Wynn TA. Type 2 cytokines: mechanisms and therapeutic strategies. Nat Rev Immunol. 2015;15:271–282.
68. Lee JJ, Dimina D, Macias MP, et al. Defining a link with asthma in mice congenitally deficient in eosinophils. Science. 2004;305:1773–1776.
69. Humbles AA, Lloyd CM, McMillan SJ, et al. A critical role for eosinophils in allergic airways remodeling. Science. 2004;305:1776–1779.
70. Lee JJ, Jacobsen EA, Ochkur SI, et al. Human versus mouse eosinophils: “that which we call an eosinophil, by any other name would stain as red”. J Allergy Clin Immunol. 2012;130:572–584.
71. Clark K, Simson L, Newcombe N, et al. Eosinophil degranulation in the allergic lung of mice primarily occurs in the airway lumen. J Leukoc Biol. 2004;75:1001–1009.
72. Lee JJ, Lee NA. Eosinophil degranulation: an evolutionary vestige or a universally destructive effector function. Clin Exp Allergy. 2005;35:986–994.
73. O'Byrne PM, Inman MD, Parameswaran K. The trials and tribulations of IL-5, eosinophils and allergic asthma. J Allergy Clin Immunol. 2001;108:503–508.
74. Nair P, Pizzichini MM, Kjarsgaard M, et al. Mepolizumab for predinosone-dependent asthma with sputum eosinophilia. N Engl J Med. 2009;360:985–993.
75. Haldar P, Brightling CE, Hargadon B, et al. Mepolizumab and exacerbations of refractory eosinophilic asthma. N Engl J Med. 2009;360:973–984.
76. Bartemes KR, Iijima K, Kobayashi T, Kephart GM, McKenzie AN, Kita H. IL-33-responsive lineage CD25+CD44-hi lymphoid cells mediate innate type 2 immunity and allergic inflammation in the lungs. J Immunol. 2012;188:1503–1513.
77. Valladao AC, Frevert CW, Koch LK, Campbell DJ, Ziegler SF. STAT6 regulates the development of eosinophilic versus neutrophilic asthma in response to Alternaria alternata. J Immunol. 2016;197:4541–4551.
78. Geslewitz WE, Percopo CM, Rosenberg HF. Eosinophil persistence in vivo and sustained viability ex vivo in response to respiratory challenge with fungal allergens. Clin Exp Allergy. 2018:48:29–38.
79. Starkey MR, Jarnicki AG, Essilfie AT, et al. Murine models of infectious exacerbations of airway inflammation. Curr Opin Pharmacol. 2013;13:337–344.
80. Siegle JS, Hansbro N, Herbert C, et al. Early-life viral infection and allergen exposure interact to induce an asthmatic phenotype in mice. Respir Res. 2010;11:14.
81. Maes T, Provoost S, Lanckacker EA, et al. Mouse models to unravel the role of inhaled pollutants on allergic sensitization and airway inflammation. Respir Res. 2010;11:7.
82. Irvin CG, Bates JH. Measuring the lung function in the mouse: the challenge of size. Respir Res. 2003;4:4.
83. Drazen JM, Finn PW, DeSanctis GT. Mouse models of airway responsiveness: physiological basis of observed outcomes and analysis of selected examples using these outcome indicators. Ann Rev Physiol. 1999;61:593–625.
84. Verheijden KA, Henricks PA, Redegeld FA, Garssen J, Folkerts G. Measurement of airway function using invasive and non-invasive methods in mild and severe models for allergic airway inflammation in mice. Front Pharmacol. 2014;5:190.
85. Tomioka S, Bates JH, Irvin CG. Airway and tissue mechanics in a murine model of asthma: alveolar capsule vs. forced oscillations. J Appl Physiol. 2002;93:263–270.
86. Shibly S, Klang A, Galler A, et al. Architecture and inflammatory cell composition of the feline lung with special consideration of eosinophil counts. J Comp Path. 2014;150:408–415.
87. Reinero CR. Advances in the understanding of pathogenesis, diagnostics and therapeutics for feline asthma. The Veterinary Journal. 2011;190:28–33.
88. Reinero Norri, R C, Decile KC, et al. An experimental model of allergic asthma in cats sensitized to house dust mite or Bermuda grass allergen. Int Arch Allergy Immunol. 2004;135:117–131.
89. Cahill KN, Katz HR, Cui J, et al. KIT inhibition by imatinib in patients with severe refractory asthma. N Engl J Med. 2017;376:1911–1920.
90. Cordeau ME, Joubert P, Dewachi O, Hamid Q, Lavoie JP. IL-4, IL-5 and IFN-gamma mRNA expression in pulmonary lymphocytes in equine heaves. Vet Immunol Immunopathol. 2004;97:87–96.
91. Barton AK, Gehlen H. Pulmonary remodeling in equine asthma: what do we know about mediators of inflammation in the horse. Mediators Inflamm. 2016;2016:5693205.
92. Bullone M, Vargas A, Elce Y, Martin JG, Lavoie JP. Fluticasone/salmeterol reduces remodeling and neutrophilic inflammation in severe equine asthma. Sci Rep. 2017;7:8843.
93. Leguillette R, Tohver T, Bond SL, Nicol JA, McDonald KJ. Effect of dexamethasone and fluticasone on airway hyperresponsiveness in horses with inflammatory airway disease. J Vet Intern Med. 2017;31:1193–1201.
94. Debrue M, Hamilton E, Joubert P, Lajoie-Kadoch S, Lavoie JP. Chronic exacerbation of equine heaves is associated with an increased expression of interleukin-17 mRNA in bronchoalveolar lavage cells. Vet Immunol Immunopathol. 2005;105:25–31.
95. Beadle RE, Horohov DW, Gaunt SD. Interleukin-4 and interferon-gamma gene expression in summer pasture-associated obstructive pulmonary disease affected horses. Equine Vet J. 2002;34:389–394.
96. Giguere S, Viel L, Lee E, MacKay RJ, Hernandez J, Franchini M. Cytokine induction in pulmonary airways of horses with heaves and effect of therapy with inhaled fluticasone propionate. Vet Immunol Immunopathol. 2002;85:147–158.
97. Kolm G, Zappe H, Schmid R, Riedelberger K, Van den Hoven R. Efficacy of montelukast in the treatment of chronic obstructive pulmonary disease in five horses. Vet Rec. 2003;152:804–806.
98. Lavoie JP, Pasloske K, Joubert P, et al. Lack of clinical efficacy of phosphodiesterase-4 inhibitor for treatment of heaves in horses. J Vet Intern Med. 2006;20:175–181.
99. Bullone M, Beauchamp G, Godbout M, Martin JG, Lavoie JP. Endobronchial ultrasound reliably quantified airway smooth muscle remodeling in an equine asthma model. PLoS One. 2015;10:e0136284.